Lakewood-Amedex to present at H.C. Wainwright investor conference

Lakewood-Amedex Biotherapeutics said CEO Kelvin Cooper will give a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference in New York City from Sept. 14-16, 2026. The biotech will also use the event for investor and partner meetings as it advances its Bisphosphocin antimicrobial program.

Why it matters: - Lakewood-Amedex Biotherapeutics is using the conference to raise visibility with investors and potential partners. - The company is positioning its Bisphosphocin class as a fast-acting, broad-spectrum antimicrobial approach aimed at infectious diseases and antibiotic-resistant bacteria. - The presentation could help support the company’s business and clinical development strategy ahead of future milestones.

What happened: - Lakewood-Amedex Biotherapeutics said CEO Kelvin Cooper, Ph.D., will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference. - The conference runs Sept. 14-16, 2026, in New York City. - During the event, Cooper will hold one-on-one meetings with registered investors and potential partners. - Lakewood-Amedex said the conference appearance will highlight its recent corporate achievements and anticipated milestones.

The details: - Lakewood-Amedex Biotherapeutics is a clinical-stage biotechnology company. - The company is developing the Bisphosphocin class, described as a novel class of potent, fast-acting, broad-spectrum antimicrobials. - The company says the program is intended to treat infectious diseases and reduce the threat from antibiotic-resistant bacterial strains, including MRSA and VRE. - Lakewood-Amedex also said it has become a new B2i Digital Featured Company, and a full profile is coming soon at More information. - More information about the company is available at the company's website.

Between the lines: - The conference slot suggests Lakewood-Amedex is in investor-outreach mode while it builds interest around its clinical pipeline. - The combination of a presentation and one-on-one meetings signals a push to convert scientific progress into business development conversations. - The focus on antibiotic resistance positions the company in a health area with clear unmet need and market attention.

What's next: - Lakewood-Amedex will present virtually during the September conference window. - The company is expected to continue discussing strategy, development progress, and upcoming milestones with investors and partners. - B2i Digital said a full company profile will be published soon.

The bottom line: - Lakewood-Amedex is pairing a high-profile investor conference appearance with direct outreach to support its antimicrobial development story.